Business Wire

Celltrion presents 2-year post-hoc analysis findings for subcutaneous infliximab (CT-P13 SC), highlighting dose escalation as an option for managing loss of response in ...

INCHEON, South Korea--(BUSINESS WIRE)--Celltrion today announced two-year results of subcutaneous infliximab (CT-P13 SC) dose escalation therapy at United European Gastroenterology (UEG) Week 2024 in ...

Tonix Pharmaceuticals Presented Post Hoc Analyses of Phase 3 Data on TONMYATM at the 8th International Congress on Controversies in Fibromyalgia

Company launched TONMYA, approved by the FDA as a treatment for fibromyalgia, in November 2025In post hoc analysis of the pivotal RESILIENT ...
Nasdaq

CalciMedica Presents New Data From Post Hoc Analysis Of Phase 2 CARDEA Study Of Auxora

(RTTNews) - CalciMedica Inc. (CALC), a clinical-stage biopharmaceutical company, Tuesday said it presented new data based on a post-hoc analysis from the previously completed Phase 2 CARDEA study of ...
The American Journal of Managed Care

Post Hoc Analysis Findings Offer Guidance for Anemia Management in Myelofibrosis: Pankit Vachhani, MD

A post hoc analysis of the phase 3b JUMP trial supports the real-world use of ruxolitinib with anemia supportive care to maintain dosing and clinical outcomes in patients with myelofibrosis, offering ...
EurekAlert!

New post-hoc analysis shows patients whose clinicians had access to GeneSight results for depression treatment are more likely to feel better sooner

SALT LAKE CITY, Oct. 30, 2025 – Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced a post-hoc analysis of the Precision Medicine in ...
Business Wire

Lundbeck Advances Leadership in Migraine With New Data at the American Headache Society 67th Annual Scientific Meeting

In a post-hoc analysis of the DELIVER trial, interictal periods were longer with VYEPTI compared to placebo and corresponded to higher patient-reported quality of life outcomes Individuals taking ...
The American Journal of Managed Care

Post Hoc Analysis Supports Axatilimab in Heavily Pretreated Patients With Chronic GVHD: Carrie Kitko, MD

The post hoc analysis of the AGAVE-201 trial found that axatilimab demonstrated consistent response rates in patients with chronic graft-vs-host disease (GVHD), regardless of the number or type of ...
Nasdaq

Amicus Therapeutics Publishes Positive Post-Hoc Analysis of Cipaglucosidase Alfa-Atga + Miglustat in Late-Onset Pompe Disease

Amicus Therapeutics has released a post-hoc analysis from the PROPEL study, published in Muscle and Nerve, which evaluated the efficacy of cipaglucosidase alfa-atga combined with miglustat (cipa+mig) ...
Medscape

Post-hoc Analysis Offers Hope for Novel Cholesterol Drug

MILAN, Italy — The antisense oligonucleotide vupanorsen substantially reduces very low density lipoprotein (VLDL) and remnant cholesterol levels in patients with raised lipids despite statin therapy, ...

Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT(R) Post Hoc Analysis Published in the European Journal of Preventive Cardiology

Peer-reviewed paper indicates icosapent ethyl (IPE) was associated with fewer total hospitalizations and fewer days lost due to hospitalization and death, providing additional insights on the effects ...